Viatris Inc. VTRS

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

The Motley Fool · 13d ago

Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035

GlobeNewswire Inc. · 58d ago

Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight

GlobeNewswire Inc. · 72d ago

Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

GlobeNewswire Inc. · 103d ago

Viatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight

Investing.com · 111d ago

Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight

GlobeNewswire Inc. · 112d ago

Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend

Benzinga · 146d ago

Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsight

GlobeNewswire Inc. · 175d ago

Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight

GlobeNewswire Inc. · 190d ago

These 10 S&P 500 Stocks Are Dirt Cheap This Black Friday

Benzinga · 236d ago

What Occidental Petroleum’s Latest Backer Sees in Oil’s Next Chapter

The Motley Fool · 270d ago

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs

Benzinga · 286d ago

Epinephrine Market to Size to Reach USD 5.74 Billion by 2032 as Demand for Emergency Allergy Treatments Surges – SNS Insider

GlobeNewswire Inc. · 324d ago

Saudi Arabia Generic Drugs Market Outlook Report 2025-2033 | Government Cost-Cutting, Local Manufacturing, and Public Awareness Fuel Rapid Growth

GlobeNewswire Inc. · 342d ago

Theravance Sales Jump 83 Percent

The Motley Fool · 343d ago

Postoperative Pain Management Market Poised for Transformation During the Forecast Period (2025–2034) with Rising Non-Opioid Adoption | DelveInsight

GlobeNewswire Inc. · 349d ago

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?

Benzinga · 411d ago

VTRS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

GlobeNewswire Inc. · 414d ago

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

GlobeNewswire Inc. · 415d ago

VTRS CLASS NOTICE: Viatris Inc. Investors may have been Affected by Fraud – Contact BFA Law before June 3 Court Deadline (NASDAQ:VTRS)

GlobeNewswire Inc. · 417d ago

VTRS DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important June 3 Deadline in Securities Class Action – VTRS

GlobeNewswire Inc. · 418d ago

VIATRIS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS

GlobeNewswire Inc. · 419d ago

Viatris Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. June 3, 2025 Deadline to file Lead Plaintiff Motion

GlobeNewswire Inc. · 420d ago

VTRS FRAUD: Suffer Losses on Viatris Inc.? You may have been Affected by Fraud and are Urged to Contact BFA Law (NASDAQ:VTRS)

GlobeNewswire Inc. · 423d ago